This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Agenus' (AGEN) Pipeline Progression on Track Amid Competition
by Zacks Equity Research
Agenus (AGEN) is developing its pipeline candidates and has an array of collaboration contracts to its credit that bodes well for growth.
Affimed (AFMD) Earnings and Sales Exceed Estimates in Q1
by Zacks Equity Research
Affimed (AFMD) exceeds earnings and sales estimates in the first quarter of 2019. The company also plans to focus its research and development investments.
Dr. Reddy's (RDY) Q4 Earnings Up Y/Y, Revenues Top Estimates
by Zacks Equity Research
Dr. Reddy's (RDY) fourth-quarter earnings and sales increase year over year.
Applied Genetic Technologies (AGTC) Q3 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
Applied Genetic Technologies (AGTC) delivered earnings and revenue surprises of 216.67% and 4163.60%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?
Applied Genetic Technologies (AGTC) Upgraded to Strong Buy: What Does It Mean for the Stock?
by Zacks Equity Research
Applied Genetic Technologies (AGTC) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Will Applied Genetic Technologies Continue to Surge Higher?
by Zacks Equity Research
As of late, it has definitely been a great time to be an investor in Applied Genetic.
Analysts Estimate Applied Genetic Technologies (AGTC) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Applied Genetic Technologies (AGTC) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Applied Genetic Technologies Enters Oversold Territory
by Zacks Equity Research
Applied Genetic Technologies has been on a bit of a cold streak lately, but there might be light at the end of the tunnel for this overlooked stock
Applied Genetic Technologies (AGTC) Tops Q1 Earnings and Revenue Estimates
by Zacks Equity Research
Applied Genetic Technologies (AGTC) delivered earnings and revenue surprises of 114.00% and 383.93%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?
Earnings Preview: Applied Genetic Technologies (AGTC) Q1 Earnings Expected to Decline
by Zacks Equity Research
Applied Genetic Technologies (AGTC) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Orexigen Posts Wider-than-Expected Loss in Q1, Sales Up Y/Y
by Zacks Equity Research
Orexigen Therapeutics, Inc.'s (OREX) loss of $4.67 per share in the first quarter of 2017 was significantly wider than the Zacks Consensus Estimate of a loss of $2.60 and the year-ago loss of $1.54.
Arena Pharmaceuticals (ARNA) Posts Q1 Loss, Revenues Down
by Zacks Equity Research
Arena Pharmaceuticals, Inc. (ARNA) reported loss of 9 cents per share in the first quarter of 2017, same as in the year-ago period but wider than the Zacks Consensus Estimate of a loss of 8 cents.
Perrigo Launches First to Market OTC Equivalent of Rogaine
by Zacks Equity Research
Perrigo Company plc (PRGO) announced the first-to-market launch of the over-the-counter ("OTC") version of hair re growth drug for the brand equivalent of women's Rogaine 5% minoxidil foam (minoxidil topical aerosol, 5% foam).
Spectrum (SPPI) Q4 Loss Narrower than Expected, Sales Beat
by Zacks Equity Research
Spectrum Pharmaceuticals, Inc. (SPPI) reported a loss of 22 cents per share in the fourth quarter of 2016, narrower than the Zacks Consensus Estimate of a loss of 26 cents but substantially wider than year-ago loss of 6 cents.
Applied Genetic Technologies (AGTC) Shares March Higher, Can It Continue?
by Zacks Equity Research
Applied Genetic Technologies Corporation (AGTC) has been on the move lately as the stock has risen by 16.0% in the past four weeks, and it is currently trading well above its 20-Day SMA
Tenet Healthcare (THC) to Divest Operations to Amedisys
by Zacks Equity Research
Tenet Healthcare Corporation (THC) recently announced that it has inked a deal with Amedisys, Inc. (AMED) to divest its Home Health and Hospice operations in Arizona, Illinois, Massachusetts and Texas to the latter
Molina Healthcare (MOH) Issues Revised Q4 & 2016 Results
by Zacks Equity Research
Molina Healthcare, Inc. (MOH) recently issued revised fourth quarter and full-year 2016 results.
Global Blood Therapeutics (GBT) in Focus: Stock Jumps 6.8%
by Zacks Equity Research
Global Blood Therapeutics, Inc. (GBT) saw its shares rise almost 7% in the last trading session.
Idera Pharmaceuticals (IDRA) Looks Good: Stock Up 13.3%
by Zacks Equity Research
Idera Pharmaceuticals, Inc. (IDRA) shares rose over 13% in the last trading session.
Seattle Genetics (SGEN) Loss Wider than Expected in Q4, Revenues Miss
by Zacks Equity Research
Seattle Genetics, Inc (SGEN) reported a loss of 39 cents per share, wider than the Zacks Consensus Estimate of a loss of 34 cents and wider than the year-ago loss of 18 cents.
Biogen's Multiple Sclerosis Franchise to Drive Growth in 2017
by Zacks Equity Research
We issued an updated research report on Biogen Inc. (BIIB) on Jan 16.
Implied Volatility Surging for Applied Genetic Technologies (AGTC) Stock Options
by Zacks Equity Research
Investors in Applied Genetic Technologies Corporation (AGTC) need to pay close attention to the stock based on moves in the options market lately.